Windtree Therapeutics Net Worth

Windtree Therapeutics Net Worth Breakdown

  WINT
The net worth of Windtree Therapeutics is the difference between its total assets and liabilities. Windtree Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Windtree Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Windtree Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Windtree Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Windtree Therapeutics stock.

Windtree Therapeutics Net Worth Analysis

Windtree Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Windtree Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Windtree Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Windtree Therapeutics' net worth analysis. One common approach is to calculate Windtree Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Windtree Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Windtree Therapeutics' net worth. This approach calculates the present value of Windtree Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Windtree Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Windtree Therapeutics' net worth. This involves comparing Windtree Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Windtree Therapeutics' net worth relative to its peers.

Enterprise Value

951.78 Million

To determine if Windtree Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Windtree Therapeutics' net worth research are outlined below:
Windtree Therapeutics generated a negative expected return over the last 90 days
Windtree Therapeutics has high historical volatility and very poor performance
Windtree Therapeutics may become a speculative penny stock
Windtree Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (20.29 M) with loss before overhead, payroll, taxes, and interest of (17.79 M).
Windtree Therapeutics currently holds about 11.38 M in cash with (13.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Windtree Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from benzinga.com: Dow Gains Over 100 Points Accenture Shares Plunge After Q2 Results
Windtree Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Windtree Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Windtree Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Windtree Therapeutics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Windtree Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Windtree Therapeutics backward and forwards among themselves. Windtree Therapeutics' institutional investor refers to the entity that pools money to purchase Windtree Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Blackrock Inc2024-12-31
6.0
Royal Bank Of Canada2024-12-31
2.0
Activest Wealth Management2024-12-31
2.0
Northern Trust Investments N A2024-12-31
0.0
Morgan Stanley - Brokerage Accounts2024-12-31
0.0
Armistice Capital, Llc2024-12-31
0.0
Ifp Advisors, Llc2024-12-31
0.0
Renaissance Technologies Corp2024-12-31
119.3 K
Ubs Group Ag2024-12-31
59.6 K
Geode Capital Management, Llc2024-12-31
59.2 K
Xtx Topco Ltd2024-12-31
19.5 K
Note, although Windtree Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Windtree Therapeutics' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M.

Market Cap

963.51 Million

Project Windtree Therapeutics' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(3.26)(3.42)
Return On Capital Employed(0.56)(0.58)
Return On Assets(0.72)(0.76)
Return On Equity(6.88)(6.54)
When accessing Windtree Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Windtree Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Windtree Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Windtree Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Windtree Therapeutics. Check Windtree Therapeutics' Beneish M Score to see the likelihood of Windtree Therapeutics' management manipulating its earnings.

Evaluate Windtree Therapeutics' management efficiency

Windtree Therapeutics has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.42 in 2025. Return On Capital Employed is likely to drop to -0.58 in 2025. At this time, Windtree Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 42.3 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 16.4 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 17.73  16.84 
Tangible Book Value Per Share(114.26)(108.55)
Enterprise Value Over EBITDA(0.93)(0.98)
Price Book Value Ratio 2.81  2.67 
Enterprise Value Multiple(0.93)(0.98)
Price Fair Value 2.81  2.67 
Enterprise ValueB951.8 M
Leadership effectiveness at Windtree Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue
706.0804
Quarterly Revenue Growth
(1.00)
Return On Equity
(1.51)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Windtree Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Windtree Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Windtree Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Craig Fraser over a week ago
Acquisition by Craig Fraser of 68800 shares of Windtree Therapeutics at 1.21 subject to Rule 16b-3
 
Craig Fraser over two weeks ago
Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.57 subject to Rule 16b-3
 
Steven Simonson over two weeks ago
Disposition of 100 shares by Steven Simonson of Windtree Therapeutics subject to Rule 16b-3
 
Craig Fraser over a month ago
Disposition of 334 shares by Craig Fraser of Windtree Therapeutics subject to Rule 16b-3
 
Huang James over a month ago
Disposition of 275938 shares by Huang James of Windtree Therapeutics at 12.09 subject to Rule 16b-3
 
Craig Fraser over three months ago
Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.4587 subject to Rule 16b-3
 
Bioengine Capital Inc. over three months ago
Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to Rule 16b-3
 
Craig Fraser over three months ago
Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3
 
Huang James over six months ago
Acquisition by Huang James of 1112308 shares of Windtree Therapeutics at 0.1411 subject to Rule 16b-3
 
Latkin Jed over six months ago
Insider Trading
 
Craig Fraser over six months ago
Acquisition by Craig Fraser of 2000 shares of Windtree Therapeutics at 0.9799 subject to Rule 16b-3
 
Craig Fraser over six months ago
Acquisition by Craig Fraser of 3000 shares of Windtree Therapeutics at 1.9 subject to Rule 16b-3
Windtree Therapeutics time-series forecasting models is one of many Windtree Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Windtree Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Windtree Therapeutics Earnings per Share Projection vs Actual

Windtree Therapeutics Corporate Management

George CoxVice OperationsProfile
Pratap ParuchuruExecutive DevelopmentProfile
Tracy RarickHead ManagementProfile
Diane EsqSr CounselProfile

Already Invested in Windtree Therapeutics?

The danger of trading Windtree Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Windtree Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Windtree Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Windtree Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.